Tag archive for ‘Rare diseases’
MSCP wraps up $330m sale of majority stake in Hojeij Branded Foods to Lagardere
By pharmanewsdaily On Monday, February 1st, 2021
0 Comments

Horizon Therapeutics to acquire Viela Bio for $3bn to grow rare disease portfolio

Horizon Therapeutics, an Irish biopharma company, has agreed to acquire Viela Bio, a US-based biotech company, for $53 per share in cash or about $3.05 billion in a move to significantly expand its development pipeline More...

By pharmanewsdaily On Monday, December 14th, 2020
0 Comments

AstraZeneca to acquire US biopharma company Alexion Pharmaceuticals for $39bn

AstraZeneca acquisition of Alexion Pharmaceuticals : Pharma giant AstraZeneca has signed a $39 billion deal to acquire Alexion Pharmaceuticals, a US biopharma company engaged in developing therapies for rare disorders. As More...

MSCP wraps up $330m sale of majority stake in Hojeij Branded Foods to Lagardere
By pharmanewsdaily On Saturday, November 28th, 2020
0 Comments

FDA extends PDUFA for Pegunigalsidase alfa (PRX–102) in Fabry disease

Pegunigalsidase alfa (PRX–102) update : Protalix BioTherapeutics said that the US Food and Drug Administration (FDA) has extended the prescription drug user fee act (PDUFA) date for review of pegunigalsidase alfa More...

MSCP wraps up $330m sale of majority stake in Hojeij Branded Foods to Lagardere
By pharmanewsdaily On Thursday, March 12th, 2020
0 Comments

F2G’s olorofim gets FDA ODD for mold infections and Valley Fever

F2G has bagged orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for olorofim (formerly F901318) for the treatments of invasive mold infections – invasive aspergillosis and lomentospora/scedosporium More...

By pharmanewsdaily On Saturday, January 18th, 2020
0 Comments

Merck acquires ArQule for $2.7bn to further diversify oncology pipeline

Merck acquisition of ArQule : Merck has completed its previously announced acquisition of ArQule for $20 per share or about $2.7 billion as per the latest pharma acquisition news. The pharma giant announced the More...

By pharmanewsdaily On Sunday, December 8th, 2019
0 Comments

Astellas Pharma to acquire US gene therapy company Audentes Therapeutics

Astellas acquisition of Audentes: Japanese pharma company Astellas Pharma has agreed to acquire US gene therapy company Audentes Therapeutics in an all-cash deal worth about $3 billion, as per pharma acquisition More...

By pharmanewsdaily On Saturday, November 9th, 2019
0 Comments

Celgene, Acceleron bag Reblozyl FDA approval for anemia in beta thalassemia

Reblozyl FDA approval : Celgene and Acceleron Pharma have bagged approval from the US Food and Drug Administration (FDA) for Reblozyl (luspatercept-aamt) for the treatment of anemia associated with beta thalassemia More...

By pharmanewsdaily On Thursday, October 17th, 2019
0 Comments

Alexion to acquire Achillion to strengthen rare diseases portfolio

Alexion acquisition of Achillion : Alexion Pharmaceuticals has agreed to acquire rival US pharma company Achillion Pharmaceuticals for about $930 million in an all-cash deal as per the latest pharma acquisition More...

By pharmanewsdaily On Sunday, July 7th, 2019
0 Comments

Pfizer wraps up $810m acquisition of Swiss biotech company Therachon

Pfizer acquisition of Therachon : US pharma giant Pfizer has completed its previously announced acquisition of Swiss biotech company Therachon, which is focused on rare diseases, in a deal worth up to $810 million, More...

Hamleys Beijing toy shop opening
By pharmanewsdaily On Sunday, September 30th, 2018
0 Comments

Alexion to acquire Boston-based Syntimmune in $1.2bn deal

Alexion acquisition of Syntimmune : US pharma company Alexion Pharmaceuticals has signed a deal of around $1.2 billion to acquire Syntimmune, a Boston-based clinical-stage biotech company focused on developing drugs More...